
Vybion is a developer of Intrabodies for neurodegenerative diseases, with FDA Orphan Drug Designation for INT41 in Huntington’s disease.
vybion.comCrawled Nov 21, 2026
Exosomes are 30–150 nm vesicles that transport proteins, lipids, and genetic material between cells. Research shows they influence cellular communication, immune responses, and drug delivery.
Vybion developed vectorized Intrabodies using AAV to deliver functional antibody fragments in scFv format. The company holds FDA Orphan Drug Designation for INT41 to treat Huntington’s disease, a fatal neurodegenerative condition.
Vybion develops Intrabodies for neurodegenerative diseases using scFv fragments to target protein aggregation, gene dysregulation, and toxic protein turnover.
Vybion secures orphan drug designation from regulators for **INT41**, a candidate therapy targeting **Huntington’s disease (HD)**. The company highlights INT41’s potential to address unmet medical needs in HD treatment and states it is progressing toward clinical trials. Vybion’s CEO, Lee Henderson, calls the designation a key step in advancing the drug’s development.
Vybion secures **Track One review status** for its Huntington’s disease gene therapy, **INT41**, under the **Patent Prosecution Highway (PPH)** program. The expedited review accelerates patent approval for the experimental drug targeting the neurodegenerative disorder. This status allows faster assessment of Vybion’s patent application, potentially streamlining regulatory and commercial pathways for INT41.
Vybion hosts a Huntington’s Disease Society of America-sponsored webinar introducing a new **gene therapy** for patients and caregivers. The session covers potential treatment approaches and patient considerations for Huntington’s disease. The company engages directly with the patient community to discuss emerging therapeutic options.
Vybion presents preclinical data on a gene therapy drug targeting Huntington’s disease in the *Journal of Neurodegenerative Diseases*. The therapy aims to address the neurodegenerative condition by modifying genetic pathways linked to disease progression. Researchers highlight potential mechanisms for slowing symptom development, though clinical validation remains pending.
Meridian Bioscience acquires Vybion’s infectious disease recombinant proteins and cardiac antigens to bolster its life science portfolio. The deal adds specialized diagnostic tools to Meridian’s existing product lineup, targeting clinical and research applications. Vybion, based in Ithaca, New York, develops biotech solutions for infectious and cardiovascular diagnostics.
Vybion exclusively licenses Cornell University’s ProCode platform, a configurable drug development tool for monoclonal antibody selection, affinity maturation, and protein-drug discovery. The technology improves solubility and bioactivity of biopharmaceuticals while enabling protein-protein interaction analysis. ProCode distinguishes itself through unique capabilities in library generation and protein characterization.
Vybion (formerly Viral Therapeutics, Inc.) rebrands as a biopharmaceutical developer specializing in Protein Evolution Tools. The company leverages over a decade of experience and a proprietary platform to accelerate drug development, improve production yields, and enhance bioactivity for both internal and external projects.